Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC

NCT06475755 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

178

Enrollment

OTHER

Sponsor class

Conditions

Non-Small Cell Lung Cancer
Anti Angiogenesis

Interventions

DRUG: Immunochemotherapy combined with antiangiogenic
DRUG: Immunochemotherapy

Sponsor

Tang-Du Hospital